(Q35125077)

6 August 2017

1 reference

title

Impact of donor infections on outcome of orthotopic liver transplantation (English)

1 reference

orthotopic liver transplantation

6 August 2017

main subject

liver transplantation

1 reference

based on heuristic

inferred from title

1 reference

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

1 January 2024

author name string

Michael Angelis

1

1 reference

6 August 2017

Jeffrey T. Cooper

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740786

1 January 2024

Richard B. Freeman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740786

1 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12740786

1 January 2024

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1053/jlts.2003.50094

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740786

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjlts.2003.50094

1 January 2024

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

https://onlinelibrary.wiley.com/doi/full/10.1053/jlts.2003.50094

1 January 2024

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

1 January 2024

published in

Liver Transplantation

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

451-462

1 reference

Transplanted infections: donor-to-host transmission with the allograft

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation

1 January 2024

2

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Disruption of the aortic anastomosis after heart-lung transplantation

1 January 2024

3

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transplantation of infected kidneys: clinical and experimental results

1 January 2024

4

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Staphylococcus aureus transmitted in transplanted kidneys

1 January 2024

5

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Donor sepsis is not a contraindication to cadaveric organ donation.

1 January 2024

8

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients

1 January 2024

9

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Outcome of transplantation of organs procured from bacteremic donors

1 January 2024

10

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The use of contaminated donor organs in transplantation.

1 January 2024

11

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Successful transplantation of organs retrieved from donors with bacterial meningitis.

1 January 2024

12

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The use of liver grafts from donors with bacterial meningitis

1 January 2024

13

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Renal artery rupture secondary to pretransplantation Candida contamination of the graft in two different recipients.

1 January 2024

14

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients

1 January 2024

15

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of disseminated histoplasmosis via cadaveric renal transplantation: case report

1 January 2024

16

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Organ donor screening for infectious diseases: review of practice and implications for transplantation.

1 January 2024

17

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients

1 January 2024

20

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

1 January 2024

21

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The New England Journal of Medicine

1 January 2024

22

299

958

Niermeijer

1978

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors

1 January 2024

23

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Infectivity of hepatic allografts with antibodies to hepatitis B virus

1 January 2024

25

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 January 2024

26

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient

1 January 2024

27

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

1 January 2024

28

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

1 January 2024

29

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing

1 January 2024

30

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Safe use of livers from donors with positive hepatitis B core antibody

1 January 2024

31

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor

1 January 2024

32

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

De novo and apparent de novo hepatitis B virus infection after liver transplantation.

1 January 2024

33

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy

1 January 2024

34

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The effect of pre-existing ischaemic heart disease on renal dysfunction in cardiac transplant recipients

1 January 2024

35

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Treatment of recurrent hepatitis B infection in liver transplant recipients

1 January 2024

36

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection

1 January 2024

37

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 January 2024

38

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Prevention of recurrent hepatitis B post-liver transplantation

1 January 2024

39

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Epidemiology of hepatitis C

1 January 2024

40

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience

1 January 2024

41

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Diagnostic tests for hepatitis C

1 January 2024

42

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Reinfection of liver graft by hepatitis C virus after liver transplantation

1 January 2024

43

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Hepatitis C virus recurrence after liver transplantation

1 January 2024

44

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues

1 January 2024

45

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Recurrent hepatitis C after liver transplantation

1 January 2024

46

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients

1 January 2024

48

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The outcome of liver grafts procured from hepatitis C-positive donors

1 January 2024

49

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Long-term outcome of hepatitis C infection after liver transplantation

1 January 2024

51

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus

1 January 2024

52

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 January 2024

53

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors

1 January 2024

54

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Infection in solid organ transplantation.

1 January 2024

55

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 January 2024

56

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Acquisition of donor strains of cytomegalovirus by renal-transplant recipients

1 January 2024

57

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Clinical patterns of cytomegalovirus disease after liver transplantation

1 January 2024

59

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Surveillance for CMV infection in orthotopic liver transplant recipients

1 January 2024

60

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 January 2024

61

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The economic impact of cytomegalovirus infection after liver transplantation

1 January 2024

62

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 January 2024

64

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients

1 January 2024

68

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4

1 January 2024

69

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients

1 January 2024

70

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

1 January 2024

71

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population

1 January 2024

72

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients

1 January 2024

73

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy

1 January 2024

74

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

1 January 2024

76

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 January 2024

77

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation

1 January 2024

78

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Diagnosis and treatment of transplant-related lymphoma

1 January 2024

79

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of human immunodeficiency virus by transplantation of a renal allograft, with development of the acquired immunodeficiency syndrome

1 January 2024

80

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Fatal acute HIV infection with aplastic anaemia, transmitted by liver graft

1 January 2024

81

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986

1 January 2024

82

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

The New England Journal of Medicine

1 January 2024

83

320

1754

Quarto

1989

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of Human Immunodeficiency Virus Type 1 from a Seronegative Organ and Tissue Donor

1 January 2024

84

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia

1 January 2024

88

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia

1 January 2024

89

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

HTLV-I associated myelopathy, a new clinical entity.

1 January 2024

90

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Human T-lymphotropic virus type I infection

1 January 2024

91

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA.

1 January 2024

92

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of HTLV-I by kidney transplant.

1 January 2024

93

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)

1 January 2024

94

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection

1 January 2024

95

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Human T-cell lymphotrophic virus infection in organ donors: a need to reassess policy?

1 January 2024

96

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

West Nile Virus Encephalitis

1 January 2024

99

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996

1 January 2024

106

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Morbidity and Mortality Weekly Report

1 January 2024

107

51

210

Zayas

2002

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Toxoplasmosis in pediatric recipients of heart transplants

1 January 2024

111

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of Toxoplasma gondii infection by liver transplantation.

1 January 2024

112

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Self-limited Toxoplasma parasitemia after liver transplantation

1 January 2024

113

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Disseminated toxoplasmosis after liver transplantation

1 January 2024

115

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

Transmission of malaria tertiana by multi-organ donation

1 January 2024

117

1 reference

https://api.crossref.org/works/10.1053/JLTS.2003.50094

1 January 2024

Identifiers

1 reference

6 August 2017

1 reference